Antibacterial Prodrugs to Overcome Bacterial Resistance Jubeh, Buthaina Breijyeh, Zeinab Karaman, Rafik 2020-07-21T10:33:45Z 2020-07-21T10:33:45Z 2020-03-28
dc.description.abstract Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and e ort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological e ects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. en_US
dc.description.sponsorship Acknowledgments: The authors would like to thank Al-Quds University-Scientific Research O ce for covering the publication fees for this review article. en_US
dc.identifier.issn 1420-3049
dc.language.iso en en_US
dc.publisher MDPI en_US
dc.subject prodrugs en_US
dc.subject biotransformation en_US
dc.subject targeting en_US
dc.subject β-lactam antibiotics en_US
dc.subject β-lactamases en_US
dc.subject pathogens en_US
dc.subject resistance en_US
dc.title Antibacterial Prodrugs to Overcome Bacterial Resistance en_US
dc.type Article en_US
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
1.53 MB
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
1.71 KB
Item-specific license agreed upon to submission